136
Participants
Start Date
December 2, 2019
Primary Completion Date
November 6, 2021
Study Completion Date
December 13, 2021
CVN424 Low Dose
CVN424
CVN424 High Dose
CVN424
Placebo
Placebo
New York Neurology Associates, New York
M3 Wake Research, Raleigh
Prisma Health, Greenville
NeuroTrials Research, Inc., Atlanta
Accel Research Site - Brain and Spine Institute of Port Orange, Port Orange
Charter Research, Winter Park
Premier Clinical Research Institute, Miami
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
USF Parkinson's Disease and Movement Disorders Center, Tampa
Parkinson's Disease Treatment Center of SW Florida, Port Charlotte
Nova Clinical Research, Bradenton
Optimed Research Ltd, Columbus
Neurology Diagnostics Inc, Dayton
Quest Research Institute, Farmington Hills
Parkinson's Disease and Movement Disorder Center, Kansas City
Central Texas Neurology Consultants, Round Rock
Collaborative Neuroscience Network, LLC, Long Beach
SC3 Research - Pasadena, Pasadena
Inland Northwest Research, LLC, Spokane
Boston Clinical Trials, Roslindale
Bio Behavioral Health, Toms River
Cerevance Beta, Inc.
INDUSTRY